China's Epilepsy Market Growing Rapidly; Attracting More Multinational Companies
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The Chinese anti-epilepsy drug market is expected to grow at an annual rate of roughly 30 percent in coming years, and multinational companies account for most of that market share, healthcare analysts predict